Actively Recruiting
BS01 in Patients With Retinitis Pigmentosa
Led by Bionic Sight LLC · Updated on 2026-01-23
20
Participants Needed
1
Research Sites
516 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
CONDITIONS
Official Title
BS01 in Patients With Retinitis Pigmentosa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of retinitis pigmentosa
- At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 306
You will not qualify if you...
- Prior receipt of any AAV gene therapy product
- Large amplitude nystagmus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
New Jersey Retina
Teaneck, New Jersey, United States, 07666
Actively Recruiting
Research Team
M
Minako Koga
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here